POLL: Which Recent FDA Update Was Most Exciting?

Click here to answer this week's poll.

Baricitinib FDA Approved to Treat Alopecia Areata
Dupilumab FDA Approved for AD Patients 6 months to 5 years
TMB-001 Granted FDA Breakthrough Therapy Designation
FDA Grants Priority Review for Dupilumab sBLA for Adults with Prurigo Nodularis
Tapinarof Cream 1% is FDA Approved
Related Videos
infectious disease
Related Content

TMB-001 for Congenital Ichthyosis Subtypes Tested by Dermatologists

March 10th 2023

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

September 23rd 2021

New Positive Results of Oral IL-23 Receptor Antagonist for Psoriasis

March 7th 2023

The Cutaneous Connection: Episode 30- Impact of the JAK Inhibitor Approval Delays

September 2nd 2021

FDA Accepts Bristol Myers Squibb’s sBLA for Nivolumab for Resected Stage IIB/C Melanoma

February 28th 2023

Bruce Feinberg, DO, Discusses 2023 Biosimilars Report From Cardinal Health

February 22nd 2023

TMB-001 for Congenital Ichthyosis Subtypes Tested by Dermatologists

March 10th 2023

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

September 23rd 2021

New Positive Results of Oral IL-23 Receptor Antagonist for Psoriasis

March 7th 2023

The Cutaneous Connection: Episode 30- Impact of the JAK Inhibitor Approval Delays

September 2nd 2021

FDA Accepts Bristol Myers Squibb’s sBLA for Nivolumab for Resected Stage IIB/C Melanoma

February 28th 2023

Bruce Feinberg, DO, Discusses 2023 Biosimilars Report From Cardinal Health

February 22nd 2023

TMB-001 for Congenital Ichthyosis Subtypes Tested by Dermatologists

March 10th 2023

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

September 23rd 2021

New Positive Results of Oral IL-23 Receptor Antagonist for Psoriasis

March 7th 2023

The Cutaneous Connection: Episode 30- Impact of the JAK Inhibitor Approval Delays

September 2nd 2021

FDA Accepts Bristol Myers Squibb’s sBLA for Nivolumab for Resected Stage IIB/C Melanoma

February 28th 2023

Bruce Feinberg, DO, Discusses 2023 Biosimilars Report From Cardinal Health

February 22nd 2023
© 2023 MJH Life Sciences

All rights reserved.